Vera Therapeutics (VERA) Long-Term Debt Issuances (2020)

Vera Therapeutics (VERA) posted Long-Term Debt Issuances of $602000.0 for Q2 2020, down 87.96% on a QoQ basis from $5.0 million in Q1 2020.

Vera Therapeutics (VERA) Long-Term Debt Issuances (2020) Analysis & Trends

Vera Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $602000.0 for Q2 2020.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $602000.0 in Q2 2020, while the trailing twelve-month figure through Dec 2020 was $5.6 million (changed N/A YoY) and the FY2020 annual result came in at $5.6 million, changed N/A from the prior year.
Long-Term Debt Issuances was $602000.0 for Q2 2020 at Vera Therapeutics, down from $5.0 million in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $5.0 million in Q1 2020 and bottomed at $602000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Vera Therapeutics	2.60 Bn	2.60 Bn	-	-

Download Data